Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05352581 · ClinicalTrials.gov registry record
BD Veritor™ At-Home and BD Veritor™ Professional
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 1,146
- Enrollment target
NCT05352581: Completed study, sponsored by Becton, Dickinson and Company.
NCT05352581 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 1,146 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05352581 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 1,146 participants
- Enrollment target
Study Summary
The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection symptoms. There is both an At-Home self test and test completed by a health care professional that will be completed during this study.
Primary Outcome
Positive percent agreement of the BD Veritor At-Home Assay compared to an FDA cleared/approved RT-PCR Assay
Interventions
- DIAGNOSTIC_TEST BD Veritor At-Home
- DIAGNOSTIC_TEST BD Veritor Professional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,146 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2023-04-14 |
What the finished NCT05352581 record still lists
NCT05352581 is an observational study that tracks outcomes without assigning an intervention. Its 1,146 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which BD Veritor At-Home is the first listed.
NCT05352581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05352581 about?
NCT05352581 is a clinical study titled "BD Veritor™ At-Home and BD Veritor™ Professional". The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection symptoms. There is both an At-Home self test and test completed by a health...
What is the current status of trial NCT05352581?
This trial is currently completed. The enrollment target is 1,146 participants. The study started on 2022-07-21. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT05352581?
The interventions under investigation include: BD Veritor At-Home (DIAGNOSTIC_TEST), BD Veritor Professional (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05352581?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI